KFAS
RLAY icon

Keating Financial Advisory Services’s Relay Therapeutics RLAY Stock Holding History

Keating Financial Advisory Services’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.54K Sell
510
-169
-25% -$2.45K ﹤0.01% 1268
2026
Q1 		$6.76K Hold
679
– – ﹤0.01% 1284
2025
Q4 		$5.74K Buy
+679
New +$4.84K ﹤0.01% 1241

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Keating Financial Advisory Services's RLAY Position: Q2 2026 in Review

Keating Financial Advisory Services reduced its Relay Therapeutics (RLAY) stake by 25% in Q2 2026, selling an estimated $2.45K and leaving 510 shares worth $9.54K. The position accounts for ﹤0.01% of the portfolio, ranked #1268.

Keating Financial Advisory Services first reported a position in RLAY in Q4 2025 and has held it in 3 quarters since. 258 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Keating Financial Advisory Services held 510 shares of Relay Therapeutics worth $9.54K as of Q2 2026.
  • Keating Financial Advisory Services sold 169 Relay Therapeutics shares in Q2 2026, an estimated $2.45K.
  • Relay Therapeutics made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #1268 holding.
  • Keating Financial Advisory Services first reported a position in Relay Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 258 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.